Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine | GSK
COVAX Facility is led by Gavi and aims to secure successful and equitable access to COVID-19 vaccines worldwide.
GSK
83d ago
Our intent to supply the COVAX Facility (led by @gavi and @WHO) with 200m doses of our co-developed #COVID19 #vaccine, if successful in clinical trials, is key to ensuring equitable access for every country in the world and protecting those most at risk. gsk.to/3myqN5j pic.twitter.com/ufnuOfxVJ3
7
